TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Friday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Trading Up 3.9 %

TXMD stock opened at $1.85 on Friday. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $4.35. The business’s 50 day moving average is $1.96 and its 200-day moving average is $2.13.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Friday, May 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC bought a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned about 2.57% of TherapeuticsMD as of its most recent SEC filing. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.